ØSØyvind V. Svendsen

Øyvind V. Svendsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Øyvind V. Svendsen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • David G. Le Couteur

    ANZAC Research Institute, Concord Hospital, Sydney Local Health District and Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia

    1 shared publication
  • Eike C. Struck

    Translational Vascular Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway

    1 shared publication
  • Elisabet Størset

    Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway

    1 shared publication
  • Erik Sveberg Dietrichs

    Experimental and Clinical Pharmacology Research Group, Department of Medical Biology, UiT, The Arctic University of Norway, 9037 Tromsø, Norway; Department of Clinical Pharmacology, Division of Diagnostic Services, University Hospital of North Norway, 9038 Tromsø, Norway

    1 shared publication
  • Espen Molden

    Center for Psychopharmacology Diakonhjemmet Hospital Oslo Norway

    1 shared publication
  • Jakub Pospíšil

    Vascular Biology Research Group, Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway

    1 shared publication

Latest Publications

  • Open Access

    Association between clozapine-induced hypertriglyceridemia and defenestration of liver sinusoidal endothelial cells

    by Tetyana Voloshyna, Øyvind V. Svendsen, Karolina Szafranska, Jakub Pospíšil, Eike C. Struck, Elisabet Størset, Robert L. Smith, Espen Molden, David G. Le Couteur, Victoria C. Cogger, et al.

    Clozapine is the most effective antipsychotic drug, while also causing the most severe metabolic side effects. The underlying mechanisms of these side effects appear multifactorial and are not entirely understood. We hypothesized that liver sinusoidal endothelial cells (LSEC) dysfunction is linked to the metabolic side effects of clozapine, based on known association between reduced LSEC porosity, hypertriglyceridemia and insulin resistance. Accordingly, we conducted a translational study by assessing the porosity of murine LSECs following clozapine exposure in vitro and correlating serum clozapine concentrations with metabolic parameters in routine human blood samples. The patient data showed a correlation for clozapine serum concentrations with both triglycerides (Spearman’s ρ = 0.47, P = 0.00024) and glucose levels (ρ = 0.24, P = 0.034), but no correlation with LDL cholesterol (ρ = −0.04, P = 0.82) or HDL cholesterol (ρ = −0.22, P = 0.088). The in vitro experiments showed a concentration-dependent reduction in murine LSEC porosity (P for trend = 0.00036). Together, these findings support a link between clozapine exposure and reduced LSEC porosity. This represents a promising point of intervention that potentially could expand safe access to clozapine as a highly effective antipsychotic treatment for a broader population, also in individuals at high risk for metabolic and cardiovascular side effects.